$RXRX — my investor take $RXRX is interesting because ARK buying 1.5M shares adds institutional conviction, but the bigger reason I’m watching it is that the underlying platform is starting to show more commercial validation. The Tempus relationship was extended through 2029, including a new license tied to Recursion’s RNA foundation model, while Genentech also advanced its first neuroscience target into an early discovery program. The thesis I’m watching is: AI + biological data → better drug discovery → more pharma partnerships → licensing/data revenue → partnered pipeline → successful programs → larger commercial value. The Tempus deal is particularly interesting because it shows Recursion’s AI/data platform can have value outside of its own internal drug pipeline. That’s important for me because it creates another potential monetization path. ARK’s purchase is a positive signal, and BlackRock also increased its position substantially. But I wouldn’t ignore the opposite data: 172 institutions added while 130 reduced, and RXRX insiders have reported 14 sales and 0 purchases over the past six months. The other thing I wouldn’t overvalue is today’s 13% move. With elevated short interest and active options, positioning can amplify a rally. That’s trading mechanics—not necessarily fundamental value creation. What I really want to see is: Tempus/data licensing → more pharma partnerships → upfront/milestone payments → revenue growth → lower cash burn → clinical/partnered pipeline progress → sustainable FCF. The cash position of roughly $557M gives the company some runway, which reduces immediate financing pressure, but this remains a speculative biotech/AI platform. My investor question: Can Recursion turn its AI/data platform into a repeatable commercial engine, rather than relying mainly on investor enthusiasm and future drug-development potential? That’s the part that could make $RXRX much more interesting over the next 3–5 years.